According to the Market Statsville Group (MSG), the global hyperparathyroidism treatment market size is expected to grow from USD 138.5 million in 2023 to USD 615.4 million by 2033, at a CAGR of 10.5% from 2024 to 2033.

The global hyperparathyroidism treatment market is expanding rapidly, owing to the rising hyperparathyroidism prevalence and advancements in treatment options. Hyperparathyroidism is a condition in which the parathyroid glands produce too much parathyroid hormone (PTH), resulting in abnormal calcium and phosphate levels in the blood. The market for hyperparathyroidism treatment includes a wide range of therapeutic options, including medications, surgical interventions, and complementary and alternative therapies.

Further, the rising prevalence of hyperparathyroidism, particularly among the elderly, is another factor that drives the market's growth. Changes in lifestyle, dietary habits, and hormonal imbalances are the factors that cause hyperparathyroidism. Growing awareness of the condition and early detection has increased the demand for effective treatment options.

Definition of the Global Hyperparathyroidism Treatment Market

Treatment for hyperparathyroidism refers to medical interventions and therapies that focus on controlling and dealing with the symptoms and underlying causes of hyperparathyroidism, a condition characterized by excess parathyroid hormone (PTH) production by the parathyroid glands. The treatment focuses on restoring normal calcium and phosphate levels in the blood, relieving associated symptoms, and prevent complications. The affected parathyroid glands responsible for PTH overproduction are removed during a parathyroidectomy surgical procedure. Generally, parathyroidectomy is preferred when the condition is severe, symptoms are severe, and complications such as kidney stones or bone loss have occurred.

COVID-19 Impact on the Global Hyperparathyroidism Treatment Market

Non-essential and elective procedures, such as parathyroidectomy surgeries, were frequently postponed or canceled as healthcare systems around the world focused on combating the pandemic and managing the sudden surge of COVID-19 patients. This has resulted in treatment delays for many people suffering from hyperparathyroidism, leading to prolonged symptoms and complications. Further, some patients have avoided seeking medical attention or undergoing necessary procedures due to their fear of contracting COVID-19 in healthcare settings. This unwillingness to visit healthcare facilities for diagnosis and treatment has hampered the timely management of hyperparathyroidism.

Global Hyperparathyroidism Treatment Market Dynamics

Drivers: Increasing prevalence of hyperparathyroidism   

The rising prevalence of hyperparathyroidism is a major driver of the hyperparathyroidism treatment market's growth. This condition can lead to serious health consequences and necessitates medical attention to manage symptoms and prevent complications. Globally, the prevalence of hyperparathyroidism has increased noticeably. More cases of hyperparathyroidism are being identified as medical advances enable earlier detection and diagnosis, resulting in a greater demand for treatment options. With the aging population, there is a growing pool of patients needing treatment, driving the demand for effective management strategies and therapies. Fatigue, kidney stones, bone pain, and weakened bones are all symptoms of hyperparathyroidism. If left untreated, it can lead to serious complications such as osteoporosis, kidney dysfunction, and cardiovascular problems. Thus, the demand for hyperparathyroidism treatment has witnessed a subsequent rise over the forecast period.

Restraints: Limited access to specialized care, particularly in certain regions

While advances in medical technology and treatment options have improved hyperparathyroidism outcomes, these benefits are not equally available to all people, particularly those living in rural and underdeveloped areas. These areas frequently have a scarcity of healthcare facilities, such as hospitals, clinics, and hyperparathyroidism treatment centers. As a result, people in these areas have a more difficult time getting timely and appropriate medical care for their condition. As there are no nearby healthcare facilities, patients must travel long distances, which can be both physically and financially taxing. These regions frequently lack specialized medical practitioners, such as endocrinologists, surgeons, and radiologists, who are critical in diagnosing and treating hyperparathyroidism. The availability of comprehensive and specialized care is limited due to a shortage of skilled healthcare professionals, leaving patients with few options for managing their condition.

Opportunity: Increasing demand for minimally invasive surgical procedures

Minimally invasive techniques use smaller incisions than open surgeries, resulting in less tissue damage, less blood loss, and a lower risk of infection. Patients benefit from shorter hospital stays, faster recovery, and less post-operative pain. As a result, patients increasingly prefer minimally invasive approaches, which provide a more comfortable and convenient treatment experience. Minimally invasive techniques offer precise and targeted interventions where the goal is to remove the abnormal parathyroid gland while protecting the function of the other healthy glands. Surgeons can use advanced imaging technologies such as ultrasound or intraoperative parathyroid hormone monitoring to precisely locate and remove the affected gland while minimizing damage to surrounding structures.

Scope of the Global Hyperparathyroidism Treatment Market

The study categorizes the hyperparathyroidism treatment market-based on product type, route of administration, and distribution channel area at the regional and global levels.

By Product Type Outlook (Sales, USD Million, 2019-2033)

• Parathyroid Hormone
  • Natpara
  • Others
• Vitamin D Analogue
  • Vitamin D2
  • Vitamin D3
• Calcium Supplements

By Route of Administration Outlook (Sales, USD Million, 2019-2033)

• Oral
• Parenteral

By Distribution Channel Outlook (Sales, USD Million, 2019-2033)

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales

By Region Outlook (Sales, USD Million, 2019-2033)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Italy
  • France
  • UK
  • Spain
  • Poland
  • Russia
  • The Netherlands
  • Norway
  • Czech Republic
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Malaysia
  • Thailand
  • Singapore
  • Australia & New Zealand
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Egypt
  • Rest of MEA

Parathyroid Hormone segment accounts for the largest market share by product type

Based on product type, the market is divided into parathyroid hormone, vitamin D analogue and calcium supplements. The parathyroid hormone segment accounted for the largest market share in 2022. The effectiveness of PTH analogues in managing hyperparathyroidism is a major factor contributing to the segmental growth. Synthetic PTH analogues, such as teriparatide, have shown significant efficacy in reducing excessive parathyroid hormone production and restoring calcium and phosphate balance. These medications adopted by healthcare professionals and are now considered standard treatment options for patients suffering from severe hyperparathyroidism. The continuous R&D for better treatment outcomes and increasing investment in healthcare by various emerging governments will further foster market growth. Pharmaceutical companies have invested in developing novel PTH analogue formulations and delivery methods, such as long-acting and sustained-release formulations. These developments have improved patient compliance, convenience, and overall treatment efficacy.

North America accounted for the largest market share by Region

Based on the regions, the global hyperparathyroidism treatment market has been segmented across Europe, North America, the Middle East & Africa, Asia-Pacific, and South America. North America dominated the global market with over 36% share in 2023. The increased prevalence, advancements in medical technology, and awareness are all factors that augment the market’s growth in North America. Another factor is the general public's growing awareness and education about hyperparathyroidism. Awareness campaigns, medical conferences, and online platforms have all played important roles in spreading information about the condition, its symptoms, and treatment options. As a result, more people are seeking medical advice and seeking early intervention.

Competitive Landscape: Global Hyperparathyroidism Treatment Market

The hyperparathyroidism treatment market is a significant competitor and extremely cutthroat in the sector is using strategies including product launches, partnerships, acquisitions, agreements, and growth to enhance their market positions. Most sector businesses focus on increasing their operations worldwide and cultivating long-lasting partnerships.

Major key players in the global hyperparathyroidism treatment market are:

• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Entera Bio Ltd. 
• Amgen Inc. 
• Ascendis Pharma A/S 
• F. Hoffmann-La Roche Ltd
• ProLynx, Inc.
• Extend Biosciences, Inc.
• BionPharma Inc.
• Teva Pharmaceuticals Ltd.

Recent Development

• In May 2023, Pathalys Pharma, Inc. and Launch Therapeutics collaborated to accelerate the enrollment for the upacicalcet development program. The companies announced the enrollment of the first patient in the PATH (PTH Attenuation Trial in Hemodialysis) clinical program, with two identical phase 3 trials, to evaluate upacicalcet for the treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis with end-stage kidney disease (ESKD).
• In August 2022, Ascendis Pharma A/S submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon PTH, a prodrug designed to restore parathyroid hormone (PTH [1-34]) over 24 hours in adult patients with hypoparathyroidism. TransCon PTH has been designated as an orphan in the European Union and the United States.